Table 2.

Multivariable logistic regression analysis of risk factors for vaccination non-response in 153 HD-patients (group A) after three (a) or in 163 HD-patients (group B) after three and more (b) SARS-CoV-2 vaccinations.

(a)
Variable	RC-B	p -Level	Exponent-B	95%-CI
boost to lab (days)	0.016	0.082	1.016	0.998	1.034
Age (years)	0.034	0.200	1.035	0.982	1.090
Active malignancy	1.142	0.300	3.134	0.362	27.170
(b)
Variable	RC-B	p -Level	Exponent-B	95%-CI
boost to lab (days)	0.008	0.287	1.008	0.993	1.023
Age (years)	0.064	0.004	1.066	1.020	1.114
Active malignancy	0.458	0.617	1.581	0.263	9.494
isMedication	2.112	0.002	8.267	2.206	30.975

(a) Variables with evidence of a relevant influence on the outcome parameter on univariable regression analysis were then examined in a multivariate model. Here, only time elapsed from third booster vaccination to laboratory measurement of SARS-CoV-2 antibody titers showed a meaningful impact on the outcome parameter defined as neutralizing antibody titers <50%. RC-B = regression coefficient, 95%-CI = 95% confidence interval of exponent-B. (b) Variables with evidence of a relevant influence on the outcome parameter on univariable regression analysis were then examined in a multivariate model. Here, only the factors age and presence of immunosuppressive medication were identified as risk factors for vaccination non-response defined as “neutralizing antibody titers below 50% and/or need for repeat vaccination” even after a third booster vaccination. RC-B = regression coefficient, 95%-CI = 95% confidence interval of exponent-B. Data of a sensitivity analysis are presented in the results section.